Evidence map›Paper›PMID 25598080›Full record

Trial reportJournal of lipid research2015

Biomarkers of NAFLD progression: a lipidomics approach to an epidemic.

D Lee Gorden, David S Myers, Pavlina T Ivanova, Eoin Fahy, Mano R Maurya, Shakti Gupta, Jun Min, Nathanael J Spann, Jeffrey G McDonald, Samuel L Kelly and 23 more

Abstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of lipid research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 212 papers.

0numbers the graph read from it
0cells of the map it votes in
212citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

212 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Gut microbial alterations and functional shifts in patients with hypertriglyceridemia: insights from a northwestern Chinese metagenomic study.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Cholesterol-containing lipid crystals can directly stiffen the rat steatotic liver before fibrosis.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  13. PlasmaHepatology forum · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

152 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

D Lee GordenDepartments of Surgery, Vanderbilt University Medical Center, Nashville, TN; Cancer Biology, Vanderbilt University Medical Center, Nashville, TN.
David S MyersPharmacology, Vanderbilt University Medical Center, Nashville, TN.
Pavlina T IvanovaPharmacology, Vanderbilt University Medical Center, Nashville, TN.
Eoin FahyDepartment of Bioengineering, School of Engineering, University of California, San Diego, La Jolla, CA.
Mano R MauryaDepartment of Bioengineering, School of Engineering, University of California, San Diego, La Jolla, CA.
Shakti GuptaDepartment of Bioengineering, School of Engineering, University of California, San Diego, La Jolla, CA.
Jun MinDepartment of Bioengineering, School of Engineering, University of California, San Diego, La Jolla, CA.
Nathanael J SpannDepartments of Cellular and Molecular Medicine and Medicine, University of California, San Diego, La Jolla, CA.
Jeffrey G McDonaldDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX.
Samuel L KellySchools of Biology, Chemistry, and Biochemistry, and the Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA.
Jingjing DuanSchools of Biology, Chemistry, and Biochemistry, and the Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA.
M Cameron SullardsSchools of Biology, Chemistry, and Biochemistry, and the Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA.
Thomas J LeikerDepartment of Pharmacology, University of Colorado at Denver, Aurora, CO.
Robert M BarkleyDepartment of Pharmacology, University of Colorado at Denver, Aurora, CO.
Oswald QuehenbergerDepartments of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA; Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA.
Aaron M ArmandoPharmacology, School of Medicine, University of California, San Diego, La Jolla, CA.
Stephen B MilnePharmacology, Vanderbilt University Medical Center, Nashville, TN.
Thomas P MathewsPharmacology, Vanderbilt University Medical Center, Nashville, TN.
Michelle D ArmstrongPharmacology, Vanderbilt University Medical Center, Nashville, TN.
Chijun LiDepartment of Biochemistry, Duke University Medical Center, Durham, NC.
Willie V MelvinDepartments of Surgery, Vanderbilt University Medical Center, Nashville, TN.
Ronald H ClementsDepartments of Surgery, Vanderbilt University Medical Center, Nashville, TN.
M Kay WashingtonPathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN.
Alisha M MendonsaCancer Biology, Vanderbilt University Medical Center, Nashville, TN.
Joseph L WitztumDepartments of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA.
Ziqiang GuanDepartment of Biochemistry, Duke University Medical Center, Durham, NC.
Christopher K GlassDepartments of Cellular and Molecular Medicine and Medicine, University of California, San Diego, La Jolla, CA.
Robert C MurphyDepartment of Pharmacology, University of Colorado at Denver, Aurora, CO.
Edward A DennisPharmacology, School of Medicine, University of California, San Diego, La Jolla, CA; Chemistry and Biochemistry, School of Medicine, University of California, San Diego, La Jolla, CA.
Alfred H MerrillSchools of Biology, Chemistry, and Biochemistry, and the Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA.
David W RussellDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX.
Shankar SubramaniamDepartment of Bioengineering, School of Engineering, University of California, San Diego, La Jolla, CA; Chemistry and Biochemistry, School of Medicine, University of California, San Diego, La Jolla, CA. Electronic address: shankar@ucsd.edu.
H Alex BrownPharmacology, Vanderbilt University Medical Center, Nashville, TN; Biochemistry, and the Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center, Nashville, TN. Electronic address: alex.brown@vanderbilt.edu.

Funding

STEROL LIPIDSU54GM069338 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DENNIS, EDWARD A · 2003 to 2013
$72.2M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Transcriptional Genomics CoreP01DK074868 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLASS, CHRISTOPHER K · 2007 to 2016
$16.6M
Shear Regulation of MicroRNA Transportomes and Targetomes in Vascular HomeostasisR01HL106579 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHIEN, SHU, SHYY, JOHN YJ · 2011 to 2022
$8.3M
LIPID Metabolites And Pathways Strategy (LIPID MAPS)R24GM107784 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FAHY, EOIN · 2013 to 2015
$1.5M
Postdoctoral Training in CNS Drug Discovery ResearchT32MH093366 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2011 to 2015
$1.0M
NHLBI NIH HHS R01 HL106579NIDDK NIH HHS P01 DK074868NIDDK NIH HHS P30 DK058404NIGMS NIH HHS GM U54 069338NIGMS NIH HHS R24 GM107784NIMH NIH HHS T32 MH093366
6 · The paper itself

Abstract

The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic steatohepatitis (NASH), and cirrhosis. Recognition and timely diagnosis of these different stages, particularly NASH, is important for both potential reversibility and limitation of complications. Liver biopsy remains the clinical standard for definitive diagnosis. Diagnostic tools minimizing the need for invasive procedures or that add information to histologic data are important in novel management strategies for the growing epidemic of NAFLD. We describe an "omics" approach to detecting a reproducible signature of lipid metabolites, aqueous intracellular metabolites, SNPs, and mRNA transcripts in a double-blinded study of patients with different stages of NAFLD that involves profiling liver biopsies, plasma, and urine samples. Using linear discriminant analysis, a panel of 20 plasma metabolites that includes glycerophospholipids, sphingolipids, sterols, and various aqueous small molecular weight components involved in cellular metabolic pathways, can be used to differentiate between NASH and steatosis. This identification of differential biomolecular signatures has the potential to improve clinical diagnosis and facilitate therapeutic intervention of NAFLD.

Indexed as

Non-alcoholic Fatty Liver DiseasePolymorphism, Single NucleotideAdultBiomarkersDouble-Blind MethodFemaleHumansLipidsMaleMiddle AgedBiomarkersLipidsdiagnostic toolsmass spectrometrynonalcoholic fatty liver diseasenonalcoholic steatohepatitisphospholipidssphingolipids

Identifiers

PMID25598080
PMCPMC4340319

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.